Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 6

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis

Authors Callejas-Rubio JL, López-Pérez L, Ortego-Centeno N

Published 5 December 2008 Volume 2008:4(6) Pages 1305—1313

DOI https://doi.org/10.2147/TCRM.S967

José Luis Callejas-Rubio, Lourdes López-Pérez, Norberto Ortego-Centeno

Unit of Autoimmune Systemic Diseases, Hospital Clinico San Cecilio, Granada, Spain

Abstract: Sarcoidosis is a chronic multisystem disease of unknown etiology, characterized by noncaseating granulomatous infiltration of virtually any organ system. Treatment is often undertaken in an attempt to resolve symptoms or prevent progression to organ failure. Previous studies have suggested a prominent role for tumor necrosis factor-alpha (TNF-α) in the inflammatory process seen in sarcoidosis. TNF-α and interleukin-1 are released by alveolar macrophages in patients with active lung disease. Corticosteroids have proved to be efficacious in the treatment of sarcoidosis, possibly by suppressing the production of TNF-α and other cytokines. Three agents are currently available as specific TNF antagonists: etanercept, infliximab, and adalimumab. Although data from noncomparative trials suggest that all three have comparable therapeutic effects in rheumatoid arthritis, their effects in a granulomatous disease such as sarcoidosis are less consistent. In this review, current data on the effectiveness are summarized.

Keywords: sarcoidosis, infliximab, etanercept, adalimumab, anti-TNA alpha

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Evaluation of glycophenotype in breast cancer by quantum dot-lectin histochemistry

Andrade CG, Cabral Filho PE, Tenorio DPL, Santos BS, Beltrão EIC, Fontes A, Carvalho Jr LB

International Journal of Nanomedicine 2013, 8:4623-4629

Published Date: 2 December 2013

Pharmacokinetics, tissue distribution, and metabolites of a polyvinylpyrrolidone-coated norcantharidin chitosan nanoparticle formulation in rats and mice, using LC-MS/MS

Ding XY, Hong CJ, Liu Y, Gu ZL, Xing KL, Zhu AJ, Chen WL, Shi LS, Zhang XN, Zhang Q

International Journal of Nanomedicine 2012, 7:1723-1735

Published Date: 2 April 2012

Association between calcifying nanoparticles and placental calcification

Guo Y, Zhang D, Lu H, Luo S, Shen X

International Journal of Nanomedicine 2012, 7:1679-1686

Published Date: 27 March 2012

Treating glioblastoma multiforme with selective high-dose liposomal doxorubicin chemotherapy induced by repeated focused ultrasound

Yang FY, Teng MC, Lu M, Liang HF, Lee YR, Yen CC, Liang ML, Wong TT

International Journal of Nanomedicine 2012, 7:965-974

Published Date: 21 February 2012

Frontal brain dysfunction in alcoholism with and without antisocial personality disorder

Marlene Oscar-Berman, Mary M Valmas, Kayle s Sawyer, Shalene M Kirkley, et al.

Neuropsychiatric Disease and Treatment 2009, 5:309-326

Published Date: 25 May 2009

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

Silent myocardial infarction in women with type II diabetes mellitus and microalbuminuria

Elmir Omerovic, Gerhard Brohall, Markus Müller, Truls Råmunddal, Göran Matejka, et al

Therapeutics and Clinical Risk Management 2008, 4:705-711

Published Date: 8 August 2008

Zoster vaccine live for the prevention of shingles in the elderly patient

Jamie Zussman, Lorraine Young

Clinical Interventions in Aging 2008, 3:241-250

Published Date: 6 June 2008

Diagnosis and treatment of chronic rhinosinusitis: focus on intranasal Amphotericin B

Eugene B Kern, David Sherris, Angelos M Stergiou, Laura M Katz, Lisa C Rosenblatt, Jens Ponikau

Therapeutics and Clinical Risk Management 2007, 3:319-325

Published Date: 15 May 2007